185 related articles for article (PubMed ID: 20705559)
1. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Forero-Torres A; Saleh MN; Galleshaw JA; Jones CF; Shah JJ; Percent IJ; Nabell LM; Carpenter JT; Falkson CI; Krontiras H; Urist MM; Bland KI; De Los Santos JF; Meredith RF; Caterinicchia V; Bernreuter WK; O'Malley JP; Li Y; LoBuglio AF
Clin Breast Cancer; 2010 Aug; 10(4):275-80. PubMed ID: 20705559
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
Park JH; Kang MJ; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim SB
Cancer Chemother Pharmacol; 2016 Oct; 78(4):685-95. PubMed ID: 27491481
[TBL] [Abstract][Full Text] [Related]
3. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
[TBL] [Abstract][Full Text] [Related]
6. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Traina TA; Rugo HS; Caravelli JF; Patil S; Yeh B; Melisko ME; Park JW; Geneus S; Paulson M; Grothusen J; Seidman AD; Fornier M; Lake D; Dang C; Robson M; Theodoulou M; Flombaum CD; Norton L; Hudis CA; Dickler MN
J Clin Oncol; 2010 Feb; 28(4):628-33. PubMed ID: 19841327
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
[TBL] [Abstract][Full Text] [Related]
8. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
Ibrahim NK; Yariz KO; Bondarenko I; Manikhas A; Semiglazov V; Alyasova A; Komisarenko V; Shparyk Y; Murray JL; Jones D; Senderovich S; Chau A; Erlandsson F; Acton G; Pegram M
Clin Cancer Res; 2011 Nov; 17(21):6822-30. PubMed ID: 21878535
[TBL] [Abstract][Full Text] [Related]
12. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Allevi G; Strina C; Andreis D; Zanoni V; Bazzola L; Bonardi S; Foroni C; Milani M; Cappelletti MR; Gussago F; Aguggini S; Giardini R; Martinotti M; Fox SB; Harris AL; Bottini A; Berruti A; Generali D
Br J Cancer; 2013 Apr; 108(8):1587-92. PubMed ID: 23579222
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
14. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Kim J; Lim W; Kim EK; Kim MK; Paik NS; Jeong SS; Yoon JH; Park CH; Ahn SH; Kim LS; Han S; Nam SJ; Kang HS; Kim SI; Yoo YB; Jeong J; Kim TH; Kang T; Kim SW; Jung Y; Lee JE; Kim KS; Yu JH; Chae BJ; Jung SY; Kang E; Choi SY; Moon HG; Noh DY; Han W
BMC Cancer; 2014 Mar; 14():170. PubMed ID: 24612502
[TBL] [Abstract][Full Text] [Related]
15. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
16. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
[TBL] [Abstract][Full Text] [Related]
17. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Mayer IA; Abramson VG; Isakoff SJ; Forero A; Balko JM; Kuba MG; Sanders ME; Yap JT; Van den Abbeele AD; Li Y; Cantley LC; Winer E; Arteaga CL
J Clin Oncol; 2014 Apr; 32(12):1202-9. PubMed ID: 24663045
[TBL] [Abstract][Full Text] [Related]
18. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
19. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
[TBL] [Abstract][Full Text] [Related]
20. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]